PREDICTORS OF TREATMENT RESISTANCE IN ANKYLOSING SPONDYLITIS

Authors:

Abstract:

The study aimed to determine the predictors of treatment resistance in patients with ankylosing spondylitis with a neuropathic component of pain syndrome. We examined 142 patients who were diagnosed with ankylosing spondylitis according to the modified New York criteria. Among the examined patients, 113 (79.6 %) were men, and 29 (20.4 %) were women; the average age was 42±8.8 years, and the duration of the disease was 6.8±3.5 years. The control group consisted of 25 practically healthy individuals (19 men and 6 women) of the same age. It was found that in patients with ankylosing spondylitis with the presence of a neuropathic component of pain syndrome, the level of glial neurotrophic factor (GDNF) was significantly (p<0.05) lower not only compared to the control group: 2,644±1,166 pg/ml vs. 4,959±2,070 pg/ml, but also compared to patients without neuropathic pain: 4.344±2.936 pg/ml (p<0.05). To determine the predictors of resistance to treatment of ankylosing spondylitis, we followed the results of 12 – week treatment of 43 patients who were divided into two groups depending on the content of glial neurotrophic factor (up to 3.0 pg/ml, 21 patients) and with normal GDNF levels (over 3.0 pg/ml, 22 patients) before treatment. The proportion of ASAS20 responders among patients with normal GDNF levels was three times higher than among patients with reduced GDNF levels: 45.5 % vs. 14.3 %, p<0.05. Thus, reduced plasma GDNF levels are associated with a more severe course of the disease, higher activity of the pathological process, poorer functional capacity, quality of life, the state of the affective sphere of patients, and a poorer response to treatment, which allows us to consider reduced levels of glial neurotrophic factor as a predictor of resistance to therapy.

Keywords:

ankylosing spondylitis neuropathic pain glial neurotrophic factor predictors of resistance

References:

1. Kedyk IO, Stanislavchuk MA. Rivni glyalnogo neurotrofichnogo faktoru v krovi hvoryh na ankilozivnyi spondylit: zvyazok z neurupatychnym komponentom boliovogo syndromu. Ukr. Reumat. Zurnal. 2023. 92(2): 47-52. DOI: 10.32471/rheumatology.2707-6970.92.17877 [in Ukrainian].
2. Cintrón-Colón AF, Almeida-Alves G, Boynton AM, Spitsbergen JM. GDNF synthesis, signaling, and retrograde transport in motor neurons. Cell Tissue Res. 2020. Vol. 382(1). P. 47-56. doi: 10.1007/s00441-020-03287-6.
3. Duarte Azevedo M, Sander S, Tenenbaum L. GDNF, A Neuron-Derived Factor Upregulated in Glial Cells during Disease. J Clin Med. 2020. Vol. 9(2). P. 456. doi: 10.3390/jcm9020456.
4. Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani FG. Ankylosing Spondylitis. J Ophthalmic Vis Res. 2021. Vol. 29. 16(3). P. 462-469. doi: 10.18502/jovr.v16i3.9440.
5. Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clin. Rheumatol. 2021. 40(8). P. 3079-3093.
6. Karra R, Holten-Rossing S, Mohammed D, Parmeggiani L, Heine M, Namnún OC. Unmet needs in the management of functional impairment in patients with chronic pain: a multinational survey. Pain Manag. 2021. Vol. 11. P. 303-314
7. Kenyon M, Maguire S, Rueda Pujol A, O'Shea F, McManus R. The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease. Rheumatol. Int. 2022. Vol. 42(12). P. 2085-2095.
8. Knotkova H, Hamani C, Sivanesan E, et al. Neuromodulation for chronic pain. Lancet. 2021. Vol. 397(10289). P. 2111-2124. doi: 10.1016/S0140-6736(21)00794-7.
9. Ma M, Li H, Wang P, Yang W, Mi R, Zhuang J, et.al. ATF6 aggravates angiogenesis-osteogenesis coupling during ankylosing spondylitis by mediating FGF2 expression in chondrocytes. iScience. 2021. Vol. 24(7). P. 102791.
10. Mahato AK, Sidorova YA. Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease. Cell Tissue Res. 2020. Vol. 382(1). P. 147-160
11. Messina DN, Peralta ED, Acosta CG. Glial-derived neurotrophic factor regulates the expression of TREK2 in rat primary sensory neurons leading to attenuation of axotomy-induced neuropathic pain. Exp. Neurol. 2022. Vol. 357. P. 114190. doi: 10.1016/j.expneurol.2022.114190
12. Mitsikostas DD, Moka E, Orrillo E, Aurilio C, Vadalouca A, Paladini A, Varrassi G. Neuropathic Pain in Neurologic Disorders: A Narrative Review. Cureus. 2022. Vol. 14(2). P. e22419.
13. Runeberg-Roos P, Penn RD. Improving therapeutic potential of GDNF family ligands. Cell Tissue Res. 2020. Vol. 382(1). P. 173-183
14. Shapoval I, Maievskyi O, Kovalchuck O, Tsyryuk O, Pellicano R, Stanislavchuk M. Circadian rhythms of plasma brain-derived neurotrophic factor in ankylosing spondylitis patients: the fibromyalgia relationship. Minerva Biotechnol Biomol Res. 2021. Vol. 2(33). С. 102-108. DOI: 10.23736/S2724-542X.21.02776-0.
15. Zhdan V.M., Tkachenko M.V., Kіtura E.M., Babanina M.Y., Kyrian O.A. Osteoarthritis and metabolic syndrome: unity of pathogenetic mechanisms. World of Medicine and Biology. 2021. Vol 4 (78). P. 56-60. DOI: 10.26724/2079-8334-2021-4-78-56-60.

Publication:

«World of Medicine and Biology» Vol. 21 No. 94 (2025) , с. 100-105
УДК 616.711-002.616.8-009.7:577.112

DOI:

https://doi.org/10.26724/2079-8334-2025-4-94-100-105